Report · S7682
FDA OCET BAA Overview and Priorities — selected contract metadata, October 25, 2023
The 2023 FDA presentation repeats 75F40120C00176 as an FDA/OMHHE collaboration studying COVID-19 illness in diverse populations. It provides a later official account of the same funding relationship described in 2022, rather than a new independent study or award. Nolan’s connection comes from the separate MaxFuse acknowledgement; no classified UAP access is reported.
Read the document at fda.govWhat we checked
Root received/hash-verified original 21-leaf FDA PDF and read native extracted leaves 1,12,17. One selected native layout actually viewed; full document graphics/layouts and executed agreements/modifications remain unreviewed. All available web-extracted text read, without complete native graphical meaning or verified live delivery.
Partial root native PDF text and selected layout review
How we check sources
Not checked yet
- Full parent native layouts/graphics and complete illustrated document remain unreviewed; one selected layout viewed.
- Original executed contracts, modifications, task statements and current obligations/payment history not reviewed.
- Institution/project support is not a named Nolan principal-investigator finding, personal payment or classified UAP approach.
- Same contract has differing award-table and later presentation descriptions; original amendment/naming history remains unknown.
- Published and file metadata dates remain distinct. No operational study/protocol, patient records or claimed personal briefing reviewed.
Cite this record
Robert Orr, U.S. Food and Drug Administration. FDA OCET BAA Overview and Priorities — selected contract metadata, October 25, 2023. October 25, 2023. BioParity S7682. https://bioparity.io/sources/S7682Record data (JSON)